NewEdge Advisors’s CalciMedica CALC Stock Holding History

NewEdge Advisors’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-71	Closed	-$285	–	3489
2023 Q2	$285	Buy	+71	New	+$310	﹤0.01%	3362
2023 Q1	–	Sell	-71	Closed	-$1	–	3520
2022 Q4	$1	Buy	+71	New	+$796	﹤0.01%	3986

Other funds holding CALC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MPM

Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NewEdge Advisors's CALC Position: Q3 2023 in Review

NewEdge Advisors sold out of CalciMedica (CALC) in Q3 2023, closing a stake of 71 shares — an estimated $285 sold.

NewEdge Advisors first reported a position in CALC in Q4 2022 and held it in 2 quarters. The position peaked at $285 in Q2 2023. 13 funds tracked by Wall St. Rank hold CALC as of Q3 2023.

NewEdge Advisors reported no remaining CalciMedica position as of Q3 2023 after selling out during the quarter.
NewEdge Advisors sold 71 CalciMedica shares in Q3 2023, an estimated $285.
NewEdge Advisors first reported a position in CalciMedica in Q4 2022 and held it in 2 quarters.
NewEdge Advisors's CalciMedica position peaked at $285 in Q2 2023.
13 funds tracked by Wall St. Rank held CalciMedica as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.